valeant pharmaceuticals inte
(VRX:New York Consolidated)
Transactions by VALEANT PHARMACEUTICALS INTE (VRX) in the last 6 months
Valeant Pharmaceuticals International, Inc. (TSX:VRX) announces a share repurchase program. Under the program, the company will repurchase up to $2,000 million worth of its common shares, senior notes and/or other debt or shares that may be issued prior to the completion of the program. The repurchases of common shares will be made at prevailing market prices of such shares on the NYSE or the TSX, as the case may be, at the time of the acquisition and will be made in ...
Valeant Pharmaceuticals International, Inc. (TSX:VRX) acquired Nicox Inc. from Nicox SA (ENXTPA:COX) for $20 million in cash on November 17, 2014. Valeant has acquired Nicox Inc. for $10 million in cash, plus further cash payments of up to $10 million based upon Valeant achieving certain sales targets with the transferred products. Valeant has acquired most of the Nicox commercial infrastructure in the US associated with diagnostics, while Nicox has retained a number ...
Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into an agreement to acquire ophthalmology and orthopaedics divisions from CROMA-PHARMA GmbH on September 22, 2014. As announced on November 4, 2014, Bausch & Lomb Canada Inc. completed the acquisition of CROMA Pharma Canada LTD from CROMA-PHARMA GmbH. Wolfgang Kinner, Jakob Pommer, Andreas W. Mayr and Jürgen Kittel of Dorda Brugger Jordis Rechtsanwälte GmbH acted as legal advisors for CROMA-PHARMA.
Valeant Pharmaceuticals International, Inc.
|Actavis plc||$260.90 USD||+4.38|
|Astellas Pharma Inc||¥1,654 JPY||-12.50|
|Mylan Inc/PA||$55.26 USD||+1.70|
|Shire PLC||4,522 GBp||+32.00|
|Sun Pharmaceutical Industries Ltd||811.35 INR||-18.80|
|View Industry Companies|